Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Medicare Weighing Changes to Doctor Drug Payments, Memo Shows

(Bloomberg) Feb 9, 2016 - The U.S. is mulling changes to how the Medicare program pays physicians for administering expensive cancer drugs and other medications given in doctors’ offices, according to a memo from the Centers for Medicare and Medicaid Services.

Commentary: Heaven help us.... (I am beginning to sound like DT). I wonder what idiot in Washington thought this one up....

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Incyte Falls on Jakafi Solid-Tumor Setback

(The Street) Feb 11, 2016 - Incyte is halting all clinical trials intended to expand the use of its blood cancer drug Jakaki into solid tumors due to an insufficient level of efficacy, the company said Thursday.
read article »

Sandoz Files For Approval Of Neulasta Biosimilar In Europe

(PMLiVE [UK]) Feb 11, 2016 - Novartis' Sandoz unit has filed for approval of its fifth biosimilar in Europe, this time taking aim at the market for Amgen's Neulasta.
read article »

Nano-Caging Gives a Failed Cancer Drug New Life

(STAT) Feb 10, 2016 - BIND Therapeutics describes itself as bringing nanotechnology to cancer therapy, but with an achievement announced on Wednesday a more colloquial description might be apt: The Cambridge-based biotech could help bring failed cancer drugs back from the dead — and all because of clever molecular packaging.
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Medicare Weighing Changes to Doctor Drug Payments, Memo Shows (Bloomberg)

Heaven help us.... (I am beginning to sound like DT). I wonder what idiot in Washington thought this one up....posted by: Thomas Marsland, MD

Medicare Weighing Changes to Doctor Drug Payments, Memo Shows (Bloomberg)

Medicare is trying to control what cancer medications a Medicare recipient can receive. This is not patient centered...posted by: Jennifer F

Clinical Pathways Need Oncologists in the Driver's Seat (Medscape Medical News)

Indeed pathways CAN be a useful tool to provide quality, cost effective oncology care. There are a number of studies...posted by: Thomas Marsland, MD

Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs (Forbes)

All I can say is "Political Hubris" beyond measure!posted by: Dean Gesme, MD

TV Ads for Lung Cancer Drug Are Needed, Says BMS (Medscape Medical News)

At the risk of offending my friends in the pharmaceutical industry, I strongly feel that DTC advertising is bad....posted by: Thomas Marsland, MD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Ipsos has 2 jobs posted.

Seattle Genetics has 1 job posted.

Bayer Pharmaceuticals has 1 job posted.

Touchpoint Solutions has 1 job posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

OBR Stock Picking Contest

Leader Board

Q1 2016
sunny621 -8.43%
nsinha -8.48%
jzheng -9.31%
rariden -11.07%
Alexandra.Heath -11.1%

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
CYTR +16.39%
FGEN +13.53%
RNN +10.42%
INCY -12.18%
RDUS -11.27%
BCRX -6.11%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: February 11, 2016
Company: Incyte Corp.
Product: Jakafi® (ruxolitinib)

Date: February 2016
Company: Heron Therapeutics
Product: SUSTOL® (granisetron) Injection

Date: Q1 2016
Company: Celldex Therapeutics, Inc.
Product: Rintega® (rindopepimut)

See All OBR Radar items»